Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
 
next
study
previous
study
c19early.org COVID-19 treatment researchVitamin DVitamin D (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis       

Vitamin D Deficiency and ARDS after SARS-CoV-2 Infection

Faul et al., Irish Medical Journal, 113:5, 84
Jun 2020  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Ventilation 69% Improvement Relative Risk Vitamin D for COVID-19  Faul et al.  Sufficiency Are vitamin D levels associated with COVID-19 outcomes? Retrospective 33 patients in Ireland Lower ventilation with higher vitamin D levels (p=0.03) c19early.org Faul et al., Irish Medical J., 84, Jun 2020 Favorsvitamin D Favorscontrol 0 0.5 1 1.5 2+
Vitamin D for COVID-19
8th treatment shown to reduce risk in October 2020, now with p < 0.00000000001 from 122 studies, recognized in 9 countries.
No treatment is 100% effective. Protocols combine treatments.
5,100+ studies for 112 treatments. c19early.org
Analysis of 33 hospitalized COVID-19 patients with respiratory failure requiring FiO2 greater than 0.4.
Intubation hazard ratio for vitamin D sufficiency HR 0.31, p = 0.03.
This is the 5th of 211 COVID-19 sufficiency studies for vitamin D, which collectively show higher levels reduce risk with p<0.0000000001 (1 in 248,027,826 vigintillion).
risk of mechanical ventilation, 69.0% lower, RR 0.31, p = 0.03, high D levels 4 of 21 (19.0%), low D levels 8 of 12 (66.7%), NNT 2.1, adjusted per study, >30nmol/L.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Faul et al., 30 Jun 2020, retrospective, Ireland, peer-reviewed, 9 authors.
This PaperVitamin DAll
Abstract: Issue: Ir Med J; Vol 113; No. 5; P84 Vitamin D Deficiency and ARDS after SARS-CoV-2 Infection J.L. Faul1, C.P. Kerley1, B. Love2, E. O’Neill3, C. Cody4, W. Tormey5, K. Hutchinson6, L.J. Cormican1, C.M. Burke1 1. 2. 3. 4. 5. 6. Asthma Research Centre, James Connolly Memorial Asthma Research Centre, Connolly Hospital Blanchardstown, Ireland. Department of Pharmacy, Connolly Hospital Blanchardstown, Ireland. Department of Microbiology, Connolly Hospital Blanchardstown and Department of Clinical Microbiology, Royal College of Surgeons in Ireland. Department of Intensive Care Medicine, Connolly Hospital Blanchardstown, Ireland. Department of Clinical Chemistry, Connolly Hospital Blanchardstown, Ireland. Eurofins-Biomnis Limited, Sandyford, Dublin, Ireland. In Response to Article Entitled ‘Optimisation of Vitamin D Status for Enhanced Immuno-Protection against Covid-19’ by D.M McCartney et al - Ir Med J; Vol 113; No. 4; P58 Dear Sir, Male gender, age over 40 years, cancer, diabetes mellitus, and chronic respiratory and cardiovascular disease have each been associated with increased severity of disease, including ARDS, after SARS-CoV-2 infection.1,2 We hypothesize that nutrition might also play a role. Vitamin D (25OHD) deficiency has previously been linked to a greater susceptibility to viral infection, ARDS, and pneumonia.3,4 Since 25OHD deficiency is both highly prevalent and easily treatable and the morbidity, mortality, and costs of SARS-CoV-2 related ARDS are great, we wanted to explore whether 25OHD levels might be associated with an increased risk of the development of ARDS due to SARS-CoV-2. Following institutional review board approval and informed consent from participants, we analyzed serum 25OHD levels in 33 adult, male, Caucasian patients, over the age of 40 years, who were admitted to Connolly Hospital Blanchardstown for SARS-CoV-2 related pneumonia (four quadrant infiltrates on chest radiograph, with respiratory failure requiring FiO2 greater than 0.4, with SARS-CoV-2 detectable by RT-PCR of nasopharyngeal swab) during March 2020. None had cancer, diabetes mellitus, cardiovascular disease, or had received chronic immunosuppressive therapy. Twelve progressed to ARDS and required intubation and mechanical ventilation. There were four deaths after mechanical ventilation (at days 3, 6, 7, and 15) in the ARDS group and none in the non-ARDS group. Overall, the twelve patients who progressed to ARDS (mean age 60 years, SD 15) had a lower serum 25OHD level on presentation to hospital (mean = 27, SD = 12 nmol.l-1), compared to the twenty one patients hospitalized with less severe pneumonia who did not progress to ARDS (mean age 56 years, SD 14). Their 25OHD level was 41 nmol.l-1 (SD 19) (p = 0.03). Vitamin D (25OHD) deficiency is highly prevalent in Ireland, a country with low levels of sunlight. Using our measures of 25OHD levels from 5374 Irish males aged between 40 and 60 years, the median is 47 nmol.l-1, with 31 and 65 nmol.l-1 representing the 25th and 75th centiles, respectively. We took a cutoff of 30 nmol.l-1, or less, as being very likely to have Vitamin D deficiency. In this cohort of thirty three patients, twelve had a baseline 25OHD level less than 30 nmol.l-1. In patients with SARS-CoV-2 related pneumonia a baseline serum 25OHD level less than 30 nmol.l-1 was associated with a hazard ratio (HR) for intubation of 3.19 (95 percent confidence interval, 1.05 to 9.7), (p = 0.03). A plausible interpretation of these early..
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit